

FIG. 1

TABLE 4
R-Groups for MATE reagents and bifunctional MoDE final compounds

MAT01 A	
MAT01 B	

FIG. 2

TABLE 1
R-Groups for MATE reagents and bifunctional MoDE final compounds

MAT01C	
MAT01D	
MAT01F	
MAT01G	

FIG. 2 (CONT.)

MAT01H	
MAT01I	
MAT01J	
MAT01K	

FIG. 2 (CONT.)

Low risk	Moderate risk	High risk	Very high risk
• Normal eGFR, proteinuria <3.5 g/d and serum albumin >30 g/l OR • Normal eGFR, proteinuria <3.5 g/d or a decrease >50% after 6 months of conservative therapy with ACEi/ARB	• Normal eGFR, proteinuria >3.5 g/d and no decrease >50% after 6 months of conservative therapy with ACEi/ARB AND • Not fulfilling high-risk criteria	• eGFR <60 ml/min/1.73 m²* and/or proteinuria >8 g/d for >6 months OR • Normal eGFR, proteinuria >3.5 g/d and no decrease >50% after 6 months of conservative therapy with ACEi/ARB AND at least one of the following: • Serum albumin <25 g/l* • PLA2Rab >50 RU/ml* • Urinary α1-microglobulin >40 µg/min • Urinary IgG >1 µg/min • Urinary β2-microglobulin >250 mg/d • Selectivity index >0.23*	• Life-threatening nephrotic syndrome OR • Rapid deterioration of kidney function not otherwise explained



FIG. 3


Anti-PLA2R binder
(bicyclic 31mer)
Azidohomoalanine
attachment site
ASGPR binder
(αGN3)

FIG. 4


BGN3
HN
W-Q-D-K-G-I-F-V-I--Q-S-E-S-L-K-Ac-C-I-Q--A-G-Ac-S-V-L-T-L-E-N--C-Ac
O
AA#4
P-M-012
alphaGN3
HN
W-Q-D-K-G-I-F-V-I--Q-S-E-S-L-K-Ac-C-I-Q--A-G-Ac-S-V-L-T-L-E-N--C-Ac
O
AA#4
P-M-013
BGN3
HN
W-Q-D-K-G-I-F-V-I--Q-S-E-S-L-K-K-C-I-Q--A-G-K-S-V-L-T-L-E-N--C-K
O
AA#2
P-M-009
BGN3
HN
W-Q-D-K-G-I-F-V-I--Q-S-E-S-L-K-K-C-I-Q--A-G-K-S-V-L-T-L-E-N--C-Ac
O
AA#4
P-M-010
BGN3
HN
W-Q-D-K-G-I-F-V-I--Q-S-E-S-L-K-Ac-C-I-Q--A-G-K-S-V-L-T-L-E-N--C-K
O
AA#2
P-M-011

FIG. 4 (CONT.)


Anti-PLA2R degrader conjugation methods
= GN3
Sortase
ABT817
ABT819
Sortase
TBT544
ABGN34
AGN635
MATE
ABT818
TBT307
AGN579
Maleimide
ABT740
TBT506
AGN167
CysR
C

FIG. 5


CvsR
AGN634 (ABT817 sortase conjugated with TBT544)
CvsR
FnIII
CLTD-1
AGN635 (ABT819 sortase conjugated with TBT544)

FIG. 6


CLTD-1
FnII
CvsR
AGN167 (ABT740 maleimide conjugated with TBT506)

FIG. 7


Attached at K248 of Fc (DAR2 per molecule)
CysR
Fnll
CTLD1
CTLD1
Fnl
CysR
AGN579 (ABT818 MATE conjugated with TBT307)

FIG. 8


anti-PLA2R Competitive ELISA
RU/mL
800
600
400
200
50
40
30
20
10
0
No competition
AGN 364
AGN 365
PLA2R ECD

FIG. 9